To include your compound in the COVID-19 Resource Center, submit it here.

Bausch + Lomb option to MIM-D3 terminated

Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) said an option was terminated

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE